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MicroRNA 92a-2*
A Biomarker Predictive for Chemoresistance and Prognostic for
Survival in Patients with Small Cell Lung Cancer
Aarati R. Ranade, PhD,* David Cherba, PhD,‡ Shravan Sridhar,* Patrick Richardson, MS,‡
Craig Webb, PhD,‡ Anoor Paripati, MBBS,† Brad Bowles,† and Glen J. Weiss, MD*†
Purpose: Although the majority of patients with small cell lung
cancer (SCLC) respond to initial chemotherapy, those with disease
progression at first response assessment (chemoresistance) have
inferior outcomes. There is a need for predictive biomarkers to aid
investigators in designing future clinical trials that better stratify
patients beyond standard clinical and laboratory parameters and to
identify new treatments for this patient subpopulation. We hypoth-
esized that tumor microRNAs (miRNAs) could serve as predictive
biomarkers for chemoresistance and prognostic biomarkers for sur-
vival of patients with SCLC treated with systemic chemotherapy.
Patients and Methods: SCLC samples annotated with clinical
characteristics and baseline comorbidities were available. miRNA
microarray profiling was performed on diagnostic SCLC tumor
samples, and analysis was performed using XenoBase, a data inte-
gration and discovery tool. Confirmation of the top 16 miRNA
candidates was performed using quantitative real-time polymerase
chain reaction followed by analyses to determine clinical and
miRNA biomarkers associated with chemoresistance and survival.
Results: miRNAs significantly associated with chemoresistance
were miR-92a-2* (p  0.010), miR-147 (p  0.018), and miR-
574-5p (p  0.039). By stepwise multivariate analysis, only gender
and miR-92a-2* contributed significantly to survival (p  0.023)
and (p  0.015), respectively. Baseline comorbidities were not
associated with chemoresistance or survival.
Conclusions: Higher tumor miR-92a-2* levels are associated with
chemoresistance and with decreased survival in patients with SCLC.
Tumor miR-92a-2* may have application in screening patients with
SCLC at risk for de novo chemoresistance in an effort to design
more tailored clinical trials for this subpopulation. Further validation
in independent sample sets is warranted.
Key Words: MicroRNAs, Small cell lung cancer, Biomarkers,
Chemoresistance, Survival, Chemotherapy.
(J Thorac Oncol. 2010;5: 1273–1278)
Lung cancer is by far the leading cause of cancer-relateddeaths in the United States. There is an estimated 159,390
deaths from lung cancer in 2009, accounting for about 29% of
all cancer cases detected.1 Of all the lung cancer cases
diagnosed in the Unites States, approximately 15% of lung
cancers are small cell lung cancer (SCLC). In 2009, more
than 32,000 new SCLC cases were diagnosed.1 SCLC has a
very aggressive course, with approximately 60–70% of pa-
tients having extensive-stage disease at the time of diagnosis.
Nearly 30 years ago, platinum-based chemotherapy
was used in SCLC treatment and remains the backbone of
current combination strategies. Although the majority of
patients with SCLC respond to initial chemotherapy, those
with disease progression at first response assessment (che-
moresistance) have inferior outcomes. More than 95% of
patients with SCLC eventually die of cancer.2,3 Toward
improving patient outcomes, use of predictive and prognostic
biomarkers may aid investigators and clinical trialists to
design future clinical trials that better stratify patients beyond
standard clinical and laboratory parameters. One method for
identifying prognostic biomarkers for other lung cancers has
been the use of gene expression profiling,4–6 which provides
a list of genes associated with prognosis. A major limitation
with this approach is that functional cellular phenotype is
ultimately defined by protein expression levels. Often, protein
level shows only a limited correlation with the gene expres-
sion level, as gene expression is also regulated by many
events including translational regulation. Thus, no single
“best” molecular prognostic marker has been identified for
lung cancer.
MicroRNAs (miRNAs) are small noncoding RNAs of
approximately 20–22 nucleotides of which a subset has been
implicated in cancer7 and may be useful as predictive and
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prognostic classifiers. miRNA binding to the 3 untranslated
region (3UTR) of target mRNA may result in translational
repression or mRNA cleavage depending on the degree of
miRNA and target complementarity.8 Dysregulation of miR-
NAs can lead to malignant progression in cells.9 The advan-
tage and the reason that miRNAs are expected to be better
biomarkers than gene expression markers is that a single
miRNA is capable of regulating many proteins thereby pro-
viding global information, as opposed to the single biomarker
associated with each mRNA and protein. Furthermore,
miRNA arrays can classify human cancers with fewer dis-
criminators than gene expression arrays.10 Recent studies
used miRNA microarray analysis to identify statistically
unique profiles, which could discriminate lung cancers from
noncancerous lung tissues and miRNA differences in tumor
histology.11,12 In this study, we hypothesized that tumor
miRNAs could serve as predictive biomarkers for chemore-
sistance and prognostic biomarkers for survival for patients
with SCLC treated with systemic chemotherapy.
PATIENTS AND TUMOR SAMPLES
Diagnostic tumor samples were obtained after prior
approval of the local Institutional Review Board from pa-
tients diagnosed between the period 2001 and 2007 and
receiving care and follow-up at Scottsdale Healthcare (Scotts-
dale, AZ). All patients subsequently received systemic che-
motherapy. Clinical characteristics included age at diagnosis,
gender, SCLC histology, limited- or extensive-stage disease,
smoking history, and statin use. The presence of baseline
comorbidities including cardiovascular disease (CAD), lung
disease (chronic obstructive pulmonary disease of emphy-
sema), thrombotic event (deep vein thrombosis or pulmonary
embolism), diabetes, hypertension, peripheral vascular dis-
ease (PVD), and hyperlipidemia were also available.
RNA Extraction and miRNA Microarray
Profiling
RNA was extracted from formalin-fixed, paraffin-em-
bedded SCLC tumor specimens by manually scraping (mac-
rodissection) the tumor from the slides followed by deparaf-
finization with xylene at 50°C. The pellet obtained after
centrifugation was washed in 100% ethanol and digested with
digestion buffer (RecoverAll Total Nucleic Acid Isolation,
Part # 8788G, Ambion) and proteinase K solution at 50°C for
3 hours. Total RNA was isolated using phenol and guanidine
thiocyanate and eluted in diethylpyrocarbonate water. The
concentration and purity of isolated RNA was estimated
using the ND-1000 microspectrophotometer (NanoDrop
Technologies, Wilmington, DE). A minimum of 1 g of total
RNA was used as the cutoff to proceed with hybridization to
the miRNA microarray platform (GenoExplorer microRNA
Expression System, GenoSensor Corporation, Tempe, AZ) con-
taining probes in triplicate for 880 validated human mature
miRNAs with an additional 473 validated human premiRNAs
(Sanger miRNA Registry, version 13.0, March 2009. Available
at: http://www.mirbase.org) along with positive and negative
control probes.
miRNA Microarray Data Analysis
The signal intensities for each miRNA detected on the
microarray profiling platform were normalized by sequen-
tially dividing by the mean signal intensities of the following
positive control probes: RNU6 and 5S-rRNA. miRNA anal-
ysis was performed using XenoBase version v3.4.2009.0922,
a data integration and discovery tool developed at the Van
Andel Research Institute.13 This tool integrated the clinical
data, miRNA probe data, and interaction data from the Sanger
miRNA Registry Version 14.0, September 2009.
Validation of miRNA Microarray Data by
Quantitative Real Time Polymerase Chain
Reaction Analysis
Confirmation of the top 16 candidates was performed
using quantitative real-time polymerase chain reaction (qRT-
PCR) by using the total RNA extracted from these samples
run in triplicate on a 384-well plate and normalized to
5S-rRNA and RNU6 (see Supplementary Materials and
Methods, available at: http://links.lww.com/JTO/A18).
STATISTICAL METHODS
The miRNA microarray data were stratified into groups
based on survival time and chemoresistance (defined as
disease progression by clinical or first radiologic assessment).
The top 16 individual miRNAs that were significant by p
value were selected for validation with qRT-PCR. Expression
level of the top 16 miRNA candidates for chemoresistance
were assessed for validation by qRT-PCR and normalized to
RNU6 and 5S-rRNA. Fisher’s exact test was used to identify
any significant (p  0.05) associations between baseline
comorbidities and chemoresistance. To facilitate the group
wise analysis, Kaplan-Meier plots, and clustering analysis, R
version 2.10.0 was used to analyze the data using both
univariate and multivariate Cox proportional hazards mod-
els.14 Univariate Cox proportional hazards models were used
to examine each of the clinical factors and qRT-PCR miRNA
values for significance. Those clinical factors and miRNAs
that were significant were included in a multivariate Cox
proportional hazard model. A reduced data set which in-
cluded only subjects with no missing qRT-PCR data (N 23)
and the same factors as the multivariate analysis was ana-
lyzed using a stepwise procedure which included both for-
ward and backward selection methods.15 All the Cox propor-
tional hazards analyses were performed using R version
2.10.0.14 Group wise analysis using t test, Kaplan-Meier
plots, and clustering was performed using XenoBase
v3.4.2009.0922.13 XenoBase is an informatics tool developed
at the Van Andel Research Institute that integrates clinical,
laboratory, and genomic data together with domain knowl-
edge to support integrated analysis and biomarker discovery.
XenoBase used the Sanger miRNA probe definitions and
interaction data from the Sanger miRNA Registry Version
12.0, September 2009, with individual probes updated to
current version 14.0.
RESULTS
Total RNA was extracted from 34 formalin-fixed,
paraffin-embedded SCLC tumor specimens. All 34 sam-
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ples had sufficient total RNA yield to perform miRNA
microarray profiling, whereas 28 samples had sufficient
total RNA for qRT-PCR. miRNA profiling data from all 34
cases exceeding the signal threshold intensity values by
exceeding positive control thresholds for RNU6 and 5S-
rRNA were subsequently analyzed using the XenoBase sys-
tem with 16 of the top differentially expressed miRNAs
selected for qRT-PCR assessment (Supplementary Tables
1 and 2, available at: http://links.lww.com/JTO/A19 and
http://links.lww.com/JTO/A20). Twenty-five of the 28
samples assessed by qRT-PCR had detectable expression
levels of 5S-RNA and RNU6 permitting the analysis of the
top 16 miRNAs. Baseline characteristics and survival data
for the 34 SCLC cases are shown in Table 1. The median age
was 69.09 years (range 42.52–82.48 years). There were 4
(12.1%) limited-stage and 29 (87.9%) extensive-stage pa-
tients at diagnosis.
Of the top 16 miRNA biomarker candidates for che-
moresistance by miRNA microarray analysis, three miRNAs
were significantly upregulated by qRT-PCR, including miR-
92a-2* (p  0.010), miR-147 (p  0.018), and miR-574-5p
(p  0.039). There were no significant associations between
gender or baseline comorbidities and chemoresistance. Of the
34 tumor samples analyzed, there were 30 biopsies (obtained
by bronchoscopy or by interventional radiology), two surgi-
cal biopsies, one excisional biopsy, and one fine needle
aspiration. The tissue type or organ from which tumor tissue
was collected for analysis included the following: lung/
bronchus (20), mediastinal mass (3), lymph node (3), bone
(2), liver (2), adrenal (1), pleura (1), skin (1), and sacral mass
(1). Across all miRNAs measured by qRT-PCR, expression
levels were not significantly altered based on the biopsy
location of the SCLC sample (data not shown).
By univariate analysis, gender (p  0.012), CAD (p 
0.036), and PVD (p  0.027) were significantly associated
with survival. The miRNAs associated with survival by
univariate analysis were miR-92a-2* (p  0.007), miR-147
(p  0.014), and miR-585 (p  0.031). There were no
significant associations between baseline comorbidities and
these 3 miRNAs.
Multivariate analysis using a Cox proportional hazard
model was performed using stepwise selection for the fol-
lowing factors that showed significance by univariate analy-
sis: CAD, PVD, gender, miR-92a-2*, -147, and -585. Gender
and miR-92a-2* contributed significantly to survival with
p  0.023 and p  0.015, respectively. Multivariate analyses
results are shown in Table 2. Figure 1 displays the Kaplan-
Meier survival curve for gender, illustrating that women have
significantly improved median survival compared with men
(log-rank p value  0.012). Figure 2 displays the Kaplan-
Meier survival curve for miR-92a-2*, illustrating expression
levels less than 0.24 (normalized to RNU6 and 5S-rRNA) is
associated with significantly improved median survival com-
pared with expression levels greater than 0.24 (log-rank p
value  0.0001). Because miR-92a-2* is located on the X
chromosome, we assessed for the possibility of a X-linked
gene driving survival differences. However, we did not ob-
serve a X chromosome-based link between miR-92a-2* and
gender (data not shown).
miRBase version 5.016 was queried for potential genes
targeted by miR-92a-2*. There were more than 600 potential
targets, and as expected, these differed from miR-92a-2 targets
(data not shown). Potential miR-92a-2* targets were analyzed
in wikipathway,17 and pathway analysis was then performed
in XenoBase where 14 gene targets that may have potential
drug candidates are listed in Supplementary Table 3 (avail-
able at: http://links.lww.com/JTO/A21).
DISCUSSION
Chemoresistance in cancer treatment is not new. The
ability to identify patients with SCLC at risk for de novo
chemoresistance may alter how these patients are treated in
the future. Factors that can help clinical trialists stratify
patients to the “right” study with more precision will facilitate
reaching our goal toward tailored treatment and Precision
Medicine. Taking lessons from other positive interventions
in cancer such as targeting HER2 breast cancer with HER2
agents and epidermal growth factor receptor tyrosine ki-
nase inhibitors for epidermal growth factor receptor mu-
tation non-small cell lung cancer, there is no reason that a
biologic marker cannot be applied to help develop new
treatments for the unfortunate patients with SCLC with de
novo chemoresistance.
TABLE 1. Patients and Disease Characteristics
Clinical Factors Results
Median Age (yr) (range) (N  34) 69.09 (42.52–82.48)
Gender (%) (N  34)
Male 17 (50)
Female 17 (50)
Disease stage (%) (N  33)
Limited 4 (12.1)
Extensive-stage 29 (87.9)
Baseline comorbidities (%) (N  34)
Coronary artery disease 7 (20.6)
Lung disease 11 (32.4)
Deep vein thrombosis 2 (5.9)
Diabetes 5 (14.7)
Hypertension 16 (47.1
Peripheral vascular disease 3 (8.8)
Hyperlipidemia 9 (26.5)
Cigarette pack/yr (%) (N  25)
Median (range) 40 (13–165)
Chemotherapy (%) (N  34)
Cisplatin-containing regimen 10 (29.4)
Carboplatin-containing regimen 18 (52.9)
Other 6 (17.6)
Received radiation during first-line therapy (%)
(N  16)
16 (47.1)
Response (%) (N  21)
Complete response 2 (9.5)
Partial response 13 (61.9)
Stable disease 2 (9.5)
Progressive disease 4 (19.1)
Median Survival (days) (range) (N  34) 246.5 (3–2384)
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In this study, we hypothesized that tumor miRNAs can
be applied to serve as biomarkers for chemoresistance. Three
miRNAs significantly associated with chemoresistance were
miR-92a-2*, -147, and -574-5p. Baseline comorbidities were
not associated with chemoresistance. Associations between
miRNAs and chemoresistance have recently been reported in
FIGURE 1. Survival by gender. The
green line depicts the survival curve
for females, and the red line depicts
survival curve for males. The survival
curves were found to be signifi-
cantly different with a log-rank p
value of 0.012.
TABLE 2. Survival Univariate and Multivariate Analysis
Univariate Analysis
Multivariate p
Inclusion Selection Stepwise Selectiona
HR of Death (95% CI) p HR of Death (95% CI) p HR of Death (95% CI) p
N  34
Age (yr) 1.01 (0.97–1.05) 0.600
Gender 2.54 (1.2–5.39) 0.012b 4.03 (1.13–14.3) 0.032b 3.09 (1.17–8.2) 0.023b
Lung disease 0.672 (0.307–1.47) 0.317
Statin 0.855 (0.38–1.92) 0.704
Coronary artery disease 2.48 (1.03–5.99) 0.036b 0.877 (0.183–4.21) 0.87
Hypertension 0.824 (0.405–1.67) 0.592
Diabetes 1.26 (0.473–3.38) 0.639
Congestive heart failure 2.68 (0.597–12) 0.180
Peripheral vascular disease 3.81 (1.07–13.6) 0.027b 1.14 (0.163–7.95) 0.9
Deep vein thrombosis 0.221 (0.0298–1.64) 0.105
Cigarette pack/yr (N  25) 1 (0.992–1.02) 0.495
Stage (N  33) 1.2 (0.419–3.43) 0.735
N  25
miR-92a-2* 7.78  1017 (22903–2.64  1031) 0.007b 2.57  1040 (3.28  1011–2.01  1091) 0.12 1.28  1017 (2.04  103–8.05  1030) 0.015b
miR-92b* 68.6 (0.707–6661) 0.060
miR-147 3.54  100.007 (1.66  101–7.54  1013) 0.014b 0.025 (2.60  1019–2.40  1015) 0.85
miR-198 7.29  10108 (1.84  1026–2.89  10243) 0.107
miR-206 0.00246 (3.33  1030–1.81  1024) 0.849
miR-423-5p 1.76  109 (1.60  108–1.94  1026) 0.289
miR-574-3p 9.5 (0.475–190) 0.137
miR-574-5p 4.41 (0.445–42.7) 0.196
miR-631 2.37  101 (1.21  1013–4.63  1015) 0.850
miR-744 4.51  103 (4.31  1010–4.73  104) 0.512
miR-765 5.14  1013 (6.63  1031–3.98  1057) 0.540
miR-885-5p 1.02  101 (1.77  107–5.88  108) 0.799
miR-936 1.81 (0.0183–180) 0.800
miR-1266 2.71  1054 (1.38  1059–5.32  10167) 0.345
miR-585 (N  24) 49.2 (1.09–2231) 0.031b 0.00418 (1.36  106–1.29  101) 0.18
a Data set reduced to N  23, Step wise method applied to gender, PVD, CAD, and miR-92a-2*, -147, and -585. Both forward and backward procedures were used.
b Significant when p value  0.05.
HR, hazard ratio; CI, confidence interval; PVD, peripheral vascular disease; CAD, coronary artery disease.
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the literature in other cancers primarily using in vitro cancer
cells or patient tumor tissue.18
Furthermore, when assessing clinical features and miR-
NAs for significant associations for survival, only increased
tumor miR-92a-2* was proven to be an independent prog-
nostic factor in addition to gender (Table 2). This is espe-
cially remarkable because the relatively small number of
patients in our study should be considered a limitation of the
study. On the other hand, that positive result for miR-92a-2*
obtained despite that limitation underlines the prognostic
potential of this miRNA, because other clinical features
(other than gender) were not significant in our study. Re-
cently, miRNAs have been demonstrated to be differentially
expressed between SCLC and tumor-free lung tissue from
smokers.11 To our knowledge, predictive miRNA biomarkers
associated with chemoresistance or prognostic for survival in
SCLC have not been previously published. Other prognostic
biomarkers associated with chemoresistance or survival in
SCLC have been reported,19–21 although miR-92a-2* is not
predicted to regulate these biomarkers.16
miR-92a-2* is the minor sequence and part of the
stem-loop structure that includes the mature sequence, miR-
92a-2. These sequences are located on chromosome Xq26.2,
and five other mature and minor sequence miRNAs are
situated within 10 kb. Collectively, these comprise the miR-
106-363 cluster.16 This cluster possesses close homology
with a well-described miRNA oncogene cluster, miR-17-92,
situated on chromosome 13q31.3.16,22 However, the miR-
92a* minor sequences are not 100% identical.16 miR-106-363
is overexpressed in 46% of human T-cell leukemias22 sug-
gesting this miRNA cluster also has oncogenic potential. On
the basis of our results and the oncogenic potential of this
miRNA cluster region, mechanistic studies to further eluci-
date the role of miR-92a-2* in chemoresistance and SCLC
biology would be compelling.
CONCLUSION
Our results demonstrate that higher tumor miR-
92a-2* levels are associated with chemoresistance and
with decreased survival in patients with SCLC. Tumor
miR-92a-2* may have application in screening for patients
at risk for de novo chemoresistance and prognosis evalu-
ation in SCLC in an effort to design more tailored clinical
trials in this disease. Further validation in independent
sample sets is warranted.
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